Expression and release of intercellular adhesion molecule-1 in renal-cancer patients

✍ Scribed by Manuela Santarosa; Daniela Favaro; Michele Quaia; Antonella Spada; Cosimo Sacco; Renato Talamini; Enzo Galligioni

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: French
• Weight: 550 KB
• Volume: 62
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910620307

✦ Synopsis

Abstract

We examined ICAM‐1 expression in 37 freshly dissociated renal‐cancer cell populations. Immunoperoxidase analysis revealed that 31 of the 37 renal tumors expressed ICAM‐I to various degrees; ICAM‐1 expression was significantly lower in tumor cells obtained from patients remaining tumor‐free after a median follow‐up of 60 months (mean value 24.4% ± 21) than in tumor cells obtained from the relapsed patients (mean value 40.8% ± 22), and the low expression of this molecule on the cell surface seemed to correlate with favorable clinical behavior. In 41 patients, the mean level of sICAM‐1 was 551 ± 260 ng/ml, significantly higher than normal. However, sICAM‐1 levels were significantly lower in the 20 tumor‐free (mean 467 ± 158 ng/ml) than in the 21 metastatic patients (mean 631 ± 318 ng/ml). Eleven renal‐cancer cell populations were cultured in order to examine the expression and release of ICAM‐1. All of these cells were positive for ICAM‐1 expression, which was elevated in 6 cases (> 50%) and low in the remaining 5 cases (18–35%). However, only the 5 cell populations expressing low levels of ICAM‐1 released this molecule, showing an inverse correlation with cellular expression. Five of the cell populations were treated for 48 hr with rIFN‐γ; in these cells, both ICAM‐1 expression and sICAM‐1 levels increased, although sICAM‐1 levels in the supernatants of the cell populations with constitutive high ICAM‐1 expression remained very low. © 1995 Wiley‐Liss Inc.